Antidepressant-Like and Anxiolytic-Like Effects of ZBD-2, a Novel Ligand for the Translocator Protein (18 kDa)
- 20 August 2016
- journal article
- research article
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 19 (1) , 57-68
Abstract
Activation of translocator protein (18 kDa) (TSPO) plays an important role to mediate rapid anxiolytic efficacy in stress response and stress-related disorders by the production of neurosteroids. However, little is known about the ligand of TSPO on the anxiety-like and depressive behaviors and the underlying mechanisms in chronic unpredictable mild stress (UCMS) mice. In the present study, a novel ligand of TSPO, ZBD-2 [N-benzyl-N-ethyl-2-(7,8-dihydro-7-benzyl-8-oxo-2-phenyl-9H-purin-9-yl) acetamide] synthesized by our laboratory, was used to evaluate the anxiolytic and antidepressant efficacy and to elucidate the underlying mechanisms. ZBD-2 (3 mg/kg) significantly attenuated anxiety-like and depressive behaviors in the UCMS mice, which was blocked by TSPO antagonist PK11195 (3 mg/kg). Treatment of ZBD-2 reversed the decrease in biogenic amines (norepinephrine, dopamine, and serotonin) in the brain region of hippocampus in the UCMS mice. The decreases in TSPO, GluN2B-containing N-methyl-d-aspartate (NMDA) receptors, GluA1, p-GluA1-Ser831, p-GluA1-Ser845, PSD-95, and GABAA-a2 were integrated with the increases of CaMKII and iNOS levels in the hippocampus of the UCMS mice. ZBD-2 significantly reversed the changes of above proteins. However, ZBD-2 or PK11195 treatment did not affect the levels of GluN2A-containing NMDA receptors and the total levels of GAD67. Our study provides strong evidences that ZBD-2 has a therapeutic effect on chronic stress-related disorders such as depression and anxiety through regulating the biogenic amine levels and the synaptic proteins in the hippocampus.Keywords
Funding Information
- National Natural Science Foundation of China (81325022, 31470052, 2011ZXJ09106-01C)
- Clinical Science and Technology Project Funding in Jiangsu Province (BL2012002)
This publication has 44 references indexed in Scilit:
- βCaMKII in Lateral Habenula Mediates Core Symptoms of DepressionScience, 2013
- Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtypeNeuropharmacology, 2013
- Acute stress induces down‐regulation of large‐conductance Ca2+‐activated potassium channels in the lateral amygdalaThe Journal of Physiology, 2012
- Individual Stress Vulnerability Is Predicted by Short-Term Memory and AMPA Receptor Subunit Ratio in the HippocampusJournal of Neuroscience, 2010
- Glutamate Receptors in Extinction and Extinction-Based Therapies for Psychiatric IllnessNeuropsychopharmacology, 2010
- Translocator Protein (18 kD) as Target for Anxiolytics Without Benzodiazepine-Like Side EffectsScience, 2009
- IL-1β is an essential mediator of the antineurogenic and anhedonic effects of stressProceedings of the National Academy of Sciences, 2008
- Antianxiety and antidepressant‐like effects of AC‐5216, a novel mitochondrial benzodiazepine receptor ligandBritish Journal of Pharmacology, 2004
- Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelinesJournal of Psychopharmacology, 2000
- Influence of immobilization stress on the levels of CaMKII and phospho-CaMKII in the rat hippocampusInternational Journal of Neuropsychopharmacology, 1999